Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

The Democratic Republic of the Congo (DRC) is battling one of its deadliest Ebola outbreaks in recent years. While it is driving innovation in medical science with new clinical trials and diagnostic tests, it is also a stark reminder of the urgency to contain the outbreak as soon as possible.

What Makes This Ebola Outbreak Deadlier?

According to the latest data, the death toll in DRC has now crossed 500 with at least 1,528 cases that are reported and confirmed.

While Ebola is not a new disease, the current outbreak stands apart because it is being caused by a rare strain of the virus, Bundibugyo.

Unlike previous outbreaks dominated by the Zaire strain of Ebola, the current epidemic, caused by the Bundibugyo virus, is a much less common species of the Ebola virus family.

The rarity of the strain has created unique scientific and emergency public health challenges, as there is currently no licensed vaccine designed to protect against Bundibugyo Ebola virus.

During outbreaks caused by the Zaire strain, vaccination became an important part of outbreak control. In the current epidemic, however, public health officials are being forced to rely heavily on rapid diagnosis, infection prevention, surveillance, and existing medical care.

Read more: Legionnaires' Disease Outbreak Grips NYC After At Least 14 Cases Reported Across 2 Neighborhoods

Bundibugyo Ebola Virus: Latest Developments

WHO Clears First Diagnostic Test

In a major scientific breakthrough, the World Health Organization (WHO) recently added the first molecular diagnostic test for the Bundibugyo Ebola virus to its Emergency Use Listing (EUL).

The test detects the virus's genetic material in blood samples, enabling laboratories to confirm infections more quickly and accurately.

First Treatment Trial Underway

WHO and its partners have launched the first clinical trial specifically evaluating treatments for Bundibugyo Ebola virus disease.

Researchers are testing the experimental monoclonal antibody MBP134, the antiviral drug remdesivir, and a combination of both to determine whether they can improve survival.

About Bundibugyo Ebola Virus

The Bundibugyo virus was first identified in Uganda in 2007 and has caused only a few outbreaks since then. As infections have been relatively uncommon compared to the Zaire strain, researchers have had limited opportunities to develop vaccines, treatments and diagnostic tests.

Due to this, healthcare workers have been compelled to rely primarily on rapid isolation of patients, intensive supportive care, contact tracing, and strict infection prevention measures to slow transmission.

Currently, Eastern DRC is the hotspot for the Bundibugyo Ebola outbreak, where conflict, population displacement, skepticism, and insecurity have made it difficult for health workers to reach affected locations.

Here, access to healthcare still remains uneven in many areas. Additionally, movement of people across districts and states in the country can accelerate the spread of infection significantly.

As scientists race to validate new diagnostics and evaluate experimental treatments, the Bundibugyo outbreak is becoming more than a public health emergency. It is also serving as a critical test of how quickly the global health community can develop and deploy new tools against an emerging infectious disease.

The health authorities in New York City are currently investigating an outbreak of Legionnaires' disease after at least 14 people were diagnosed with the potentially life-threatening respiratory illness across two neighborhoods in Manhattan. The recent outbreak prompted an urgent public health response.

Legionnaires' Disease Outbreak IN NYC

The outbreak, initially marked with just two cases earlier this week, has grown rapidly. Cases of infections were reported in Carnegie Hill and Yorkville on the Upper East Side.

The New York City Department of Health has immediately launched an investigation to identify the source of the outbreak and is inspecting cooling towers and other water systems in the affected areas, where the Legionella bacteria commonly thrive.

Authorities have urged residents and visitors who were in the neighborhoods in recent days to seek medical attention if they face symptoms like fever, cough or difficulty breathing.

What is Legionnaires' Disease?

The bacteria naturally occur in freshwater environments but can multiply in man-made water systems that are poorly maintained, including:

• Cooling towers used for large air-conditioning systems

• Hot tubs and spas

• Public fountains

• Large plumbing systems

• Water tanks and heaters

Read more: New Blood Test May Predict Alzheimer's Symptoms At Least 4 Years In Advance: Study

Symptoms:

Symptoms of Legionnaire's disease appear 2 to 14 days after exposure, although they can sometimes take longer. The common symptoms of Legionnaires' disease include:

• High fever

• Persistent cough

• Shortness of breath

• Chills

• Muscle aches

• Headache

Some patients, particularly older adults, may also develop nausea, vomiting, diarrhea or confusion. As the illness closely resembles other forms of pneumonia, laboratory testing is usually required to confirm the diagnosis.

Read more: Donald Trump Posts AI Video of Himself Treating Critics for 'Derangement Syndrome'

Treatment & Prevention

Legionnaires' disease is treatable with antibiotics, and early diagnosis greatly improves recovery. However, delayed treatment can lead to severe complications such as respiratory failure, septic shock, or multi-organ failure.

The disease can be fatal, especially among older adults and people with underlying health conditions.

While the overall fatality rate is around 10% in otherwise healthy individuals, it can be considerably higher in vulnerable patients if treatment is delayed.

Although most people are unlikely to be exposed, experts recommend:

• Seeking immediate medical care for pneumonia-like symptoms, particularly if you are in a high-risk group.

• Ensuring building water systems, cooling towers, and hot tubs are properly maintained.

• Avoiding smoking as it increases susceptibility to the severe disease.

• Following public health advisories during ongoing outbreak investigations.

What Should You Do If You're Infected?

If you feel ill and experience the symptoms of Legionnaire's, watch for signs, especially respiratory distress, fever, or extreme tiredness. Health officials recommend the following:

• Contact your healthcare provider immediately if symptoms appear

• Inform them of your recent travel to potentially affected areas

• Get tested if symptoms suggest pneumonia or related complications

Health Officials Act On Outbreak Control

New York City health officials are testing cooling towers and other potential environmental sources in the affected neighborhoods to identify where the bacteria may have originated. Property owners are immediately required to disinfect contaminated cooling towers if Legionella is detected.

Officials have emphasized that residents can continue using home air conditioners and public cooling centers, as these systems do not typically spread the bacteria in the same way as large industrial cooling towers.

The Maharashtra Food and Drug Administration (FDA) recently banned the sale, distribution, and use of several fairness creams after dangerous levels of toxic heavy metals, including lead and mercury, were found in the products.

About The Case

Among the products, one named Goree Beauty Cream is of Pakistani origin. The product was reportedly being sold unlawfully in the state.

The FDA labelled the products “Not of Standard Quality” (NSQ), warning consumers against using them as prolonged exposure to heavy metals present in the products can lead to serious health complications associated with skin, kidneys as well as the nervous system.

According to the Maharashtra FDA, the following cosmetic products have been declared unsafe:

1. Goree Beauty Cream
2. Face Fresh Gold
3. Golden Star Beauty Cream

Officials also noted that the products lacked mandatory information like the manufacturer's complete details, batch number, manufacturing date, and expiry date, raising concerns over their authenticity and safety.

Also read: Bryan Johnson Blames Sugary Cereals, Soda and Stress for His Autoimmune Disease; Shares Treatment Plan

What Happens When One Gets Exposed To Lead And Mercury?

If used repeatedly, these toxic substances may be absorbed through the skin, allowing them to accumulate in the body over time.

Excessive exposure to mercury can cause:

• Kidney damage

• Tremors and muscle weakness

• Numbness or tingling sensations

• Memory problems and difficulty concentrating

• Mood changes and irritability

• Skin rashes and discoloration

• Harm to unborn babies during pregnancy

The risk increases with prolonged use, particularly when the products are used on a daily basis over months or years.

Also read: Australia Reports More H5 Bird Flu Cases: Does It Have Pandemic Potential?

On the other hand, lead exposure can cause:

• Damage to the nervous system

• High blood pressure

• Kidney dysfunction

• Fertility problems

• Developmental delays in children

• Pregnancy complications

Even if lead accumulates in the body in small amounts, its repeated use may pose long-term health risks.

Why Are Lead And Mercury Found In Fairness Creams?

Sometimes, mercury is illegally added to skin-lightening products as it suppresses melanin production, temporarily making the skin appear lighter. However, this skin-lightening effect comes at the cost of significant health risks.

Lead may contaminate cosmetic products through poor-quality raw materials or unsafe manufacturing processes. Neither ingredient should be intentionally present in cosmetic creams sold for routine use.

International health agencies have repeatedly warned against skin-lightening creams containing mercury.

In June 2026, the US FDA again cautioned consumers not to use over-the-counter skin-lightening products found to contain mercury or hydroquinone because of the risk of kidney injury, neurological damage, and permanent skin problems.

The Maharashtra FDA's crackdown highlights the hidden dangers of unregulated and illegal fairness creams that contain harmful ingredients.

While these products may promise lighter skin, the presence of toxic heavy metals such as mercury and lead can expose users to potentially irreversible health damage. Consumers are advised to read the labels carefully before purchasing any skincare products that promise complexion-altering effects.